FDA ends GLP-1 compounding for semaglutide, tirzepatide

Episode notes

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide. Featuring: Sara Heath, executive editor, Xtelligent Healthcare Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare In today’s episode, we’ll cover… The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections and more! References: Anticipating the healthcare reach of GLP-1 receptor agonists Are compounded GLP-1 drugs safe? FDA winds down GLP-1 compounding policies To learn more about GLP-1s,

• Exploring rural healthcare cybersecurity resource constraints61 / 100
• Pursuing strategic partnerships to tackle Cobalt Strike abuse85 / 100
• Reshaping healthcare revenue cycle management with AI
• Balancing technology and touch with virtual nursing programs
• Peer navigators: the soul of community-based street medicine